[Form 4] 180 Life Sciences Corp. Warrant Insider Trading Activity

Rhea-AI Filing Summary

180 Life Sciences Corp. (ATNF) – Form 4 filing, 14 Jul 2025

Chief Accounting Officer Eric R. Van Lent reported changes in his beneficial ownership. The filing shows he now holds 8,174 common shares directly and a non-qualified stock option for 25,000 shares with a $0.929 exercise price.

The option was originally scheduled to vest 50 % on 17 Dec 2025 and 50 % on 17 Jun 2026. On 12 Jul 2025, the Board accelerated vesting of the entire award, making all 25,000 options fully vested as of that date. Key contingency: the options cannot be exercised until shareholders approve the company’s 2025 Option Incentive Plan; if approval is not obtained, the options will be cancelled.

No open-market purchases or sales of common stock are reported, and ownership remains direct. The disclosure signals the company’s intent to retain a key finance executive but leaves potential dilution dependent on upcoming shareholder consent.

Positive

• Executive retention signal: Board accelerated vesting of CAO’s option grant, indicating confidence in key leadership.

Negative

• Shareholder approval risk: 25,000 options will be cancelled if the 2025 Option Incentive Plan is not approved, creating uncertainty.

Insights

Equity Compensation Analyst

TL;DR: CAO received 25k options with accelerated vesting, pending shareholder approval; minimal immediate share impact.

The Form 4 centres on an administrative modification—not a new grant—of a previously disclosed 25,000-share option at $0.929. Accelerated vesting strengthens executive retention ahead of critical milestones but does not change fully-diluted share count unless shareholders ratify the 2025 plan. Because no common shares were bought or sold and the option strike remains near penny-stock territory, market impact is modest. Investors should watch the forthcoming shareholder vote: cancellation would nullify this award but avoid dilution, while approval would add a small (<1 %) increment to potential share issuance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Van Lent Eric R

(Last) (First) (Middle)

3000 EL CAMINO REAL, BLDG. 4,

SUITE 200

(Street)

PALO ALTO CA 94306

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
180 Life Sciences Corp. [ ATNF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								8,174	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$0.929							07/12/2025(1)	06/17/2035	Common Stock	25,000		25,000	D

Explanation of Responses:

1. As originally reported in the Reporting Person's Form 4/A filed with the SEC on June 30, 2025, the options were to vest 1/2 on each of December 17, 2025 and June 17, 2026, subject to the recipient's continued service to the Issuer. On July 12, 2025, the Board of Directors of the Company, with the recommendation of the Compensation Committee of the Board of Directors, approved the accelerated vesting of all the options effective as of such date. The options are subject to stockholder approval and (i) no options can be exercised prior to obtaining stockholder approval for the Company's 2025 Option Incentive Plan, and (ii) the outstanding options will be cancelled, if stockholder approval is not obtained.

	/s/ Eric Van Lent	07/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Eric Van Lent report in the ATNF Form 4?

He holds 8,174 common shares and a 25,000-share stock option at $0.929 that has been accelerated to full vesting.

When did the accelerated vesting take effect?

The Board approved full vesting on 12 July 2025.

Can the options be exercised immediately?

No. Exercise is contingent upon shareholder approval of the 2025 Option Incentive Plan.

What happens if shareholders do not approve the plan?

All 25,000 options will be cancelled, eliminating potential dilution.

Were any common shares bought or sold in this filing?

The Form 4 shows no purchases or sales; only option-related changes were reported.